Skip to main content

Drug Repurposing In Cancer Therapy

In Order to Read Online or Download Drug Repurposing In Cancer Therapy Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Drug Repurposing in Cancer Therapy

Drug Repurposing in Cancer Therapy Book
Author : Kenneth K.W. To,William C.S. Cho
Publisher : Academic Press
Release : 2020-07-29
ISBN : 0128199032
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy. Cancer researchers, oncologists, pharmacologists and several members of biomedical field who are interested in learning more about the use of existing drugs for different purposes in cancer therapy will find this to be a valuable resource. Presents a systematic and up-to-date collection of the research underpinning the various drug repurposing approaches for a quick, but in-depth understanding on current trends in drug repurposing research Brings better understanding of the drug repurposing process in a holistic way, combining both basic and clinical sciences Encompasses a collection of successful stories of drug repurposing for cancer therapy in different cancer types

Multiple Myeloma as an Example of Drug Repurposing for Cancer Treatment

Multiple Myeloma as an Example of Drug Repurposing for Cancer Treatment Book
Author : Charlotte Driessen
Publisher : Unknown
Release : 2020
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Multiple Myeloma as an Example of Drug Repurposing for Cancer Treatment book written by Charlotte Driessen, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

pH Interfering Agents as Chemosensitizers in Cancer Therapy

pH Interfering Agents as Chemosensitizers in Cancer Therapy Book
Author : Claudiu Supuran,Simone Carradori
Publisher : Academic Press
Release : 2020-09-15
ISBN : 0128209283
Language : En, Es, Fr & De

GET BOOK

Book Description :

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

An Investigation Into Mechanisms of Action of Colchicine Zinc Acetate and Paracetemol Potential Candidates for Drug Repurposing in Head and Neck Cancer Therapy

An Investigation Into Mechanisms of Action of Colchicine  Zinc Acetate and Paracetemol   Potential Candidates for Drug Repurposing in Head and Neck Cancer Therapy Book
Author : Nadia Shakir
Publisher : Unknown
Release : 2014
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download An Investigation Into Mechanisms of Action of Colchicine Zinc Acetate and Paracetemol Potential Candidates for Drug Repurposing in Head and Neck Cancer Therapy book written by Nadia Shakir, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Drug Repurposing

Drug Repurposing Book
Author : Farid A. Badria
Publisher : BoD – Books on Demand
Release : 2020-12-02
ISBN : 1839685204
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug repurposing or drug repositioning is a new approach to presenting new indications for common commercial and clinically approved existing drugs. For example, chloroquine, an old antimalarial drug, showed promising results for treating COVID-19, interfering with MDR in several types of cancer, and chemosensitizing human leukemic cells.This book focuses on the hypothesis, risk/benefits, and economic impacts of drug repurposing on drug discovery in dermatology, infectious diseases, neurological disorders, cancer, and orphan diseases. It brings together up-to-date research to provide readers with an informative, illustrative, and easy-to-read book useful for students, clinicians, and the pharmaceutical industry.

Artificial Intelligence in Oncology Drug Discovery and Development

Artificial Intelligence in Oncology Drug Discovery and Development Book
Author : John Cassidy,Belle Taylor
Publisher : BoD – Books on Demand
Release : 2020-09-09
ISBN : 1789846897
Language : En, Es, Fr & De

GET BOOK

Book Description :

There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic burden of cancer increases, the current paradigm in drug development is unsustainable. In this book, we discuss the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. We consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence.

Cracking Cancer Toolkit

Cracking Cancer Toolkit Book
Author : Jeffrey Dach
Publisher : Unknown
Release : 2020-10
ISBN : 9781732421011
Language : En, Es, Fr & De

GET BOOK

Book Description :

After three family members were stricken with aggressive cancer, I realized I had to get up to speed on the jargon of cancer research, and devise my own cancer toolkit of repurposed drugs and supplements if I wanted my loved ones to survive. This book is a record of that journey as we explore "Cancer as a Metabolic Disease" and the repurposed drugs and supplements targeting metabolic pathways for eradication of cancer stem cells. The problem is not about finding the one elusive anti-cancer drug or botanical substance. The problem is that we have too many anti-cancer substances to choose from. How do we narrow down the list and use them in an effective combination? Hopefully, this book will give you the information needed to select a few key repurposed drugs and supplements to target Cancer Stem Cells and the important metabolic pathways in a synergistic manner, resulting in the desired curative efficacy. -Jeffrey Dach, MDExcerpt from Foreword by Carol Petersen, RPh, CNP: Dr. Jeffrey Dach found himself face to face with serious cancer challenges to family members. His training in radiology gave him a platform to launch his investigation and he worked tirelessly to find information that could change a deadly outcome. His searches cover 5 years of study. He investigated practitioners and scientists who might have insights. In the end, his family members had successful outcomes. He has decided to share the information he accumulated. "Cracking Cancer Toolbox" is not a protocol nor recipe for success for any particular cancer. It is however, a gateway to learning much more about cancer than the average oncologist will relate to their patients. Knowledge is power. Reading this book and keeping it as a reference will open doors to learning new theories and potential therapies. Many therapies already exist but have been unused because of strict adherence to the narrative. Dr. Dach presents us with the gift of translation. His writing is clear and understandable. We don't have to have a PhD or medical degree to grasp concepts that come cloaked in medical jargon. This compilation of cancer information is a great work. He sends it into the world so many more can benefit. - Carol Petersen, RPh, CNPExcerpt from Foreword by Akbar Khan, MD: And now we have Dr. Jeffrey Dach's book, Cracking Cancer Toolkit, which explains the metabolic theory of cancer and other novel theories in a comprehensible writing style, understandable to the non-medical reader. Given how common cancer is today, this book is a valuable addition to any home library. Indeed, the knowledge you gain may save your life, or the life of a friend or family member. - Akbar Khan, MD About the Author: Jeffrey Dach, MD is a practicing physician, originally board certified in Diagnostic and Interventional Radiology. In 2005, Dr Dach retired from radiology and resumed outpatient clinical medicine in a small office in Davie, Florida. He is the author of Heart Book, Bioidentical Hormones 101 and Natural Medicine 101. He is co-author of Stop the Thyroid Madness Vol.2. Dr. Dach lives in Hollywood, Florida, and is married, with three adult married children, and three grandchildren. His web sites are www.jeffreydachmd.com and www.crackingcancertoolkit.com.

Drug Repurposing in Oncology Tapping Into the Potential of Data Sharing and Partnership Initiatives

Drug Repurposing in Oncology  Tapping Into the Potential of Data Sharing and Partnership Initiatives Book
Author : Isabelle Huys
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug repurposing can be broadly defined as finding new uses for existing medicines and in fact covers different development scenarios depending on the product approval status, the patent situation and the required product changes for use in the new indication. A key strategic advantage of drug repurposing over developing new chemical entities is the substantial amount of available data and knowledge regarding those medicines. The aim of this study was to map data and data sources relevant to the drug repurposing process and to investigate stakeholdersu2019 views on data sharing via databases and public-private partnerships. Scientific and grey literature was collected using defined search queries. Furthermore, 14 semi-structured interviews with representatives of the pharmaceutical industry, academia and non-profit organisations from Europe and the US were conducted between October 2017 and January 2018. Various data relevant to decision-making throughout the drug repurposing process were outlined in this study including preclinical, human trial, registration and real-world data. In addition, numerous data sources were identified (e.g., databases with target information, drug information, gene expression information, clinical trial results) and over twenty examples of online databases and partnerships with a specific focus on drug repurposing research were found (e.g., The Drug Repurposing Hub, repoDB, RE:fine Drugs). Various types of data are dispersed amongst numerous sources and stakeholders, thus complicating the creation of a robust evidence base that is needed to repurpose a medicine. Data transparency and partnerships may advance drug repurposing research, but stakeholdersu2019 concerns need to be addressed first. Based on the results from this study, we recommend providing increased guidance on collecting relevant data for decision-making throughout the drug repurposing process and creating a multidisciplinary framework that promotes data sharing whilst protecting the interests of all involved stakeholders.

Drug Repurposing and Repositioning

Drug Repurposing and Repositioning Book
Author : Institute of Medicine,Board on Health Sciences Policy,Roundtable on Translating Genomic-Based Research for Health
Publisher : National Academies Press
Release : 2014-08-08
ISBN : 0309302072
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug development can be time-consuming and expensive. Recent estimates suggest that, on average, it takes 10 years and at least $1 billion to bring a drug to market. Given the time and expense of developing drugs de novo, pharmaceutical companies have become increasingly interested in finding new uses for existing drugs - a process referred to as drug repurposing or repositioning. Historically, drug repurposing has been largely an unintentional, serendipitous process that took place when a drug was found to have an offtarget effect or a previously unrecognized on-target effect that could be used for identifying a new indication. Perhaps the most recognizable example of such a successful repositioning effort is sildenafil. Originally developed as an anti-hypertensive, sildenafil, marketed as Viagra and under other trade names, has been repurposed for the treatment of erectile dysfunction and pulmonary arterial hypertension. Viagra generated more than $2 billion worldwide in 2012 and has recently been studied for the treatment of heart failure. Given the widespread interest in drug repurposing, the Roundtable on Translating Genomic-Based Research for Health of the Institute of Medicine hosted a workshop on June 24, 2013, in Washington, DC, to assess the current landscape of drug repurposing activities in industry, academia, and government. Stakeholders, including government officials, pharmaceutical company representatives, academic researchers, regulators, funders, and patients, were invited to present their perspectives and to participate in workshop discussions. Drug Repurposing and Repositioning is the summary of that workshop. This report examines enabling tools and technology for drug repurposing; evaluates the business models and economic incentives for pursuing a repurposing approach; and discusses how genomic and genetic research could be positioned to better enable a drug repurposing paradigm.

Repurposing Metformin for Lung Cancer Management

Repurposing Metformin for Lung Cancer Management Book
Author : Chuan-Mu Chen
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

In this article, we introduced the background knowledge of lung cancer management and considered repurposing old drugs to overcome therapy bottleneck. We chose metformin to prove both its antihyperglycemia and antitumor formation effects. Based on the metformin-related AMPK-dependent pathway, we tried to explore the AMPK-independent pathway in inhibition of lung tumorigenesis by metformin. Using preclinical data mining from clinical settings with a literature review, we attempted to clarify the role of metformin in lung cancer management. Additional objective and strong evidence are needed using randomized control studies to verify the benefit of metformin in clinical practice. Furthermore, we proposed two lung cancer animal models and showed the establishment processes thoroughly. We hope that these two lung cancer animal models provide a useful platform for furthering old drug repurposing as well as new drug investigations in the future.

Drug Repositioning Current Advances and Future Perspectives

Drug Repositioning  Current Advances and Future Perspectives Book
Author : Yuhei Nishimura,Hideaki Hara
Publisher : Frontiers Media SA
Release : 2019-01-11
ISBN : 288945696X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.

Drug Repositioning

Drug Repositioning Book
Author : Joel Dudley,Laura Berliocchi
Publisher : CRC Press
Release : 2017-07-14
ISBN : 1482220849
Language : En, Es, Fr & De

GET BOOK

Book Description :

Nervous system diseases represent a major health concern worldwide. Although important financial and professional investment, their etiology and pathophysiology still remain mostly elusive. Moreover, the clinical need of disease-modifying therapies is still unmet. In the last decades, traditional R&D has failed in identifying new effective therapies in many medical areas and drug repositioning has recently emerged as a promising alternative strategy to de novo drug discovery to improve and accelerate therapeutic development. For the first time, Drug Repositioning: Approaches and Applications for Neurotherapeutics reviews history and advances in drug repositioning, with a special focus on therapeutics for nervous system diseases. International experts from Academia, Industry and Non-profit organisations will provide different views on drug repositioning advantages, challenges and specific applications, which will be covered for nervous system diseases including Alzheimer's, Parkinson's, Huntington's diseases, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, ischemic stroke, and psychiatric disorders. This book provides a balanced overview and synthesis of drug repositioning concept, methods and applications for neurotherapeutics. It represents a valuable resource for students, scientists and clinicians working in academic settings, industry and government agencies within the fields of neuroscience, pharmacology, neurology, pharmaceutical sciences, drug discovery and development.

Drug Diagnostics Co Development in Oncology

Drug Diagnostics Co Development in Oncology Book
Author : Jan Trøst Jørgensen
Publisher : Frontiers E-books
Release : 2014-11-07
ISBN : 2889193322
Language : En, Es, Fr & De

GET BOOK

Book Description :

The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area.

Drug Repositioning

Drug Repositioning Book
Author : Michael J. Barratt,Donald E. Frail
Publisher : John Wiley & Sons
Release : 2012-05-29
ISBN : 0470878274
Language : En, Es, Fr & De

GET BOOK

Book Description :

With Viagra the most famous example, drug repositioning has been growing in importance for pharmaceutical companies seeking to reinvigorate development pipelines. This book provides a broad overview of drug repositioning including the business reasons and unique opportunities and challenges. Its coverage also presents a number of current and emerging technologies that are being applied, along with relevant case studies, as well as neglected diseases to consider. Pharmaceutical researchers will learn how to use drug repositioning techniques to increase the lifespan and applications of their drugs, and also decrease both costs and development time.

In Silico Drug Design

In Silico Drug Design Book
Author : Kunal Roy
Publisher : Academic Press
Release : 2019-02-12
ISBN : 0128163771
Language : En, Es, Fr & De

GET BOOK

Book Description :

In Silico Drug Design: Repurposing Techniques and Methodologies explores the application of computational tools that can be utilized for this approach. The book covers theoretical background and methodologies of chem-bioinformatic techniques and network modeling and discusses the various applied strategies to systematically retrieve, integrate and analyze datasets from diverse sources. Other topics include in silico drug design methods, computational workflows for drug repurposing, and network-based in silico screening for drug efficacy. With contributions from experts in the field and the inclusion of practical case studies, this book gives scientists, researchers and R&D professionals in the pharmaceutical industry valuable insights into drug design. Discusses the theoretical background and methodologies of useful techniques of cheminformatics and bioinformatics that can be applied for drug repurposing Offers case studies relating to the in silico modeling of FDA-approved drugs for the discovery of antifungal, anticancer, antiplatelet agents, and for drug therapies against diseases Covers tools and databases that can be utilized to facilitate in silico methods for drug repurposing

Resistance to Targeted Therapies Against Adult Brain Cancers

Resistance to Targeted Therapies Against Adult Brain Cancers Book
Author : Amanda Tivnan
Publisher : Springer
Release : 2016-11-26
ISBN : 3319465058
Language : En, Es, Fr & De

GET BOOK

Book Description :

This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.

The Unfolded Protein Response in Cancer

The Unfolded Protein Response in Cancer Book
Author : Robert Clarke
Publisher : Springer
Release : 2019-03-01
ISBN : 303005067X
Language : En, Es, Fr & De

GET BOOK

Book Description :

This volume presents state-of-the-art information on each of the arms of the unfolded protein response (UPR), how their activation/repression are regulated, integrated, and coordinated, how UPR components affect cancer cell biology and responsiveness to therapeutic interventions, and how UPR components/activities offer potentially novel targets for drug discovery, repurposing, and development. The volume will provide the most recent information on the signaling and regulation of the UPR, explore examples of how the UPR and/or specific components contribute to cancer biology, and identify and explore specific examples of potently new actionable targets for drug discovery and development from within the UPR and its regulation. Unique to the volume will be a specific focus on the UPR and its role in cancer biology, as well as a discussion of the role of the UPR in drug responses and resistance in cancer.

Drug Selectivity

Drug Selectivity Book
Author : Norbert Handler
Publisher : John Wiley & Sons
Release : 2017-11-23
ISBN : 3527674403
Language : En, Es, Fr & De

GET BOOK

Book Description :

The book "Drug Selectivity - An Evolving Concept in Medicinal Chemistry" provides a current overview and comprehensive compilation for medicinal chemists that discusses the effects of aiming for multiple targets on the entire drug development process. The result is a broad survey of current and future strategies for drug selectivity in medicinal chemistry with theoretical but also practical aspects. Different strategies are presented and evaluated, such as various design approaches, merged multiple ligands, discovery technologies and a broad range of successful examples of unselective drugs taken from all major disease areas. With its wide-ranging view of an emerging new paradigm in drug development, this handbook is of prime importance for every medicinal and pharmaceutical chemist.

A Statin regulated MicroRNA Represses C Myc Expression and Function

A Statin regulated MicroRNA Represses C Myc Expression and Function Book
Author : Apana Agha L. Takwi
Publisher : Unknown
Release : 2011
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

c-Myc dysregulation is one of the most common abnormalities found in human cancer. MicroRNAs (miRNAs) are functionally intertwined with the c-Myc network as multiple miRNAs are regulated by c-Myc, while others directly suppress c-Myc expression. In this work, we identified miR-33b as a primate-specific negative regulator of c-Myc. The human miR-33b gene is located at 17pl1.2, a genomic locus frequently lost in medulloblastomas, which are pediatric brain tumors that display c-Myc overproduction. Through a small-scale screening with drugs approved by the US Food and Drug Administration (FDA), we found that lovastatin up-regulated miR-33b expression, reduced cell proliferation, and impaired c-Myc expression and function in miR-33b-positive medulloblastoma cells. In addition, a low dose of lovastatin treatment at a level comparable to approved human oral use reduced tumor growth in mice orthotopically xenografted with cells carrying miR-33b, but not with cells lacking miR-33b. This work presents a highly promising therapeutic option, using drug repurposing and a miRNA as a biomarker, against cancers that over-express c-Myc.

Off label Prescribing

Off label Prescribing Book
Author : David Cavalla
Publisher : John Wiley & Sons
Release : 2015-03-16
ISBN : 1118912071
Language : En, Es, Fr & De

GET BOOK

Book Description :

Today’s medicines are regulated for their efficacy and safety and, once approved, they can be marketed for certain uses as justified by the data. Regulatory bodies in developed countries are constituted by legal statute and operate as parts of government, ostensibly in the interests of the people as patients. But once approved, medicines can be used for any purpose the prescriber thinks fit and appropriate for the patient. One in five prescriptions is therefore written outside regulatory purview. Off-label Prescribing looks into the corners of our medicated lives, where drug regulation runs up against medical practice, and concerns the use of a drug that has been approved for one use (in medical parlance, ‘indication’) being used for a different indication; alternatively, being used on a different set of patients from the ones it is approved for, or at a different dose. Usually the patient is unaware of what is going on, having not been informed by their doctor of this aspect of his or her prescribing choice. The book examines how and why this occurs, what the various medical professions have to say about it, and how pharmaceutical companies benefit by moving into this poorly regulated area. Off-label Prescribing pulls these complex issues together in one volume, to highlight current practice, its advantages and weaknesses and how the author suggests practice should evolve in the future. It will therefore be of interest to all those who prescribe (and receive) medicines, combined with a greater objective to provide more transparency and discussion for professionals.